BiotechTube
Home/Libra Therapeutics/Shawn Scranton, PharmD
SS

Shawn Scranton, PharmD

Chief Executive Officer & President

Libra Therapeutics

Therapeutic Areas

Neurodegenerative DiseasesAmyotrophic Lateral SclerosisFrontotemporal DementiaAlzheimer's DiseaseParkinson's DiseaseHuntington's Disease

Libra Therapeutics Pipeline

DrugIndicationPhase
Lysofunction Platform / TRPML1Neurodegenerative Diseases (ALS, PD, etc.)Preclinical
C9orf72 RAN Translation InhibitionC9orf72-associated ALS/FTDDiscovery
C9orf72 Transcriptional ModificationC9orf72-associated ALS/FTDDiscovery
Undisclosed TargetNot DisclosedDiscovery

Leadership Team at Libra Therapeutics

MG
Martin Gill, PhD
Chief Scientific Officer
GK
Gene Kinney, PhD
Chairman of the Board
View full Libra Therapeutics profile